Clinical Trial Search

Primary: Salivary Lactic Acid Levels With Seizures — 8.16 mmol/L

Primary: Number of Subjects With a Change From Baseline Serum Lactate Following a One Hour Albuterol Nebulizer Treatment. — -0.15; 0.77 mmol/L

Primary: Change in Limb Fat at 48 Weeks — 448; 153 grams — p=0.02

Primary: Hepatic Triglyceride (%) — 15.9; 14.8 Fat/Fat+Water (%) — p=0.42

Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants

Primary: Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile — 500 mg

Primary: Lactate Level 24 Hours After the First Study Medication Dose — 2.6; 2.5 mmol/L — p=0.40

Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min

Primary: Change in Mitochondrial Activity — 1250; 1312; 1150; 1125 copies/cell

Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L

Primary: Cystine Stone Recurrence — 16; 23 Participants

Primary: Clinical Response — 32; 25; 28 Participants

Primary: Change in Fat mtDNA Content — -169; 321 copies/cell

Primary: Mitochondrial Function (mtDNA Levels) — 1372 copies per cell

Primary: Calcium — 1.88; 2.04 mmol/L

Primary: Presence of AAD — 12 participants — p=<0.05

Primary: Change in Peak Oxygen Uptake. — 2.2; 2.8 ml/Kg/min — p=<0.05

Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg

Primary: Subjects With Change From Baseline in Serum Bicarbonate of ≥ 4 mEq/L or Serum Bicarbonate Within the Normal Range — 59.2; 22.5; 55.8; 21.3 percentage of participants…

Primary: Total Symptoms Score — 2.5; 3.1 units on a scale — p=< 0.05

Primary: Patient Recruitment Rate (Feasibility Outcome) — 66 Participants

Primary: Assessing the Effect of ALA on the Blood Parameters: Lipid and Carbohydrate Framework — 180.60; 37.60; 88.80; 132 mg/dl

Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD

Primary: Proportion of the Patients Who Require Vasopressor/Mechanical Ventilator — 53; 21 participants

Primary: Muscle Strength

Primary: Spirometric FVC Values at Baseline — 2.74; 3.07 Liters

Primary: Ototoxicity Measurement — 7; 7 participants — p=0.89

Primary: Change in Mean Lactate Level of the LR Group Compared to the NS Group. — 0.93; 0.37 mmol/L

Primary: Percentage Of Participants Achieving Alanine Aminotransferase Normalization — 31; 7; 56; 37 percentage of participants — p=0.0271

Primary: Fasting Serum Triglycerides — 237; 341 mg/dL — p=0.84